Pyrazole Composition With TPGS for Poor Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound 1-[(3R,4S)-4-cyanotetrahydropyran-3-yl]-3-[(2-fluoro-6-methoxy-4-pyridyl)amino]pyrazole-4-carboxamide, a selective Janus kinase (JAK) inhibitor, suffers from poor water solubility leading to poor oral bioavailability and biological efficacy in animals.
Innovation Solution
Incorporating a surfactant, specifically D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS), an ester of tocopherol, polyethylene glycol, and a dicarboxylic acid, into a solid pharmaceutical composition enhances the bioavailability of the compound.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If the compound is formulated without surfactant, then the formulation is simple, but the oral bioavailability is poor due to poor water solubility
Solution Approach 1:
The patent introduces TPGS surfactant as an intermediary substance that mediates between the poorly water-soluble compound and the aqueous environment in the body. TPGS forms micelles that solubilize the compound, enabling it to dissolve in gastrointestinal fluids and be absorbed into the bloodstream, thus resolving the contradiction between formulation simplicity and bioavailability.
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by incorporating TPGS surfactant, which alters the solubility characteristics of the compound. The surfactant modifies the microenvironment around the compound molecules, enabling them to remain dispersed and soluble in aqueous media, thereby improving oral bioavailability without significantly complicating the manufacturing process.
2Reliability
If TPGS surfactant is added to improve solubility, then oral bioavailability improves, but the formulation complexity increases
Solution Approach 1:
The patent employs TPGS surfactant at relatively low concentrations (typically 0.1-10% w/w) where it performs its solubilization function temporarily during the digestion and absorption process. The surfactant is not required to provide long-term structural support or persistent function, allowing the formulation to remain relatively simple while achieving the desired bioavailability improvement.
3Ease of operation
If the compound is administered without surfactant, then the administration is simple, but the biological efficacy is poor
Solution Approach 1:
TPGS surfactant serves as an intermediary that facilitates the compound's journey through the gastrointestinal tract and into the bloodstream. It creates a solubilizing microenvironment that allows the compound to be absorbed intact and reach its target biological sites, thereby maintaining administration simplicity while dramatically improving biological efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The inclusion of TPGS in the formulation significantly improves the oral bioavailability of the compound, leading to enhanced biological efficacy in treating atopic dermatitis in animals.
Implementation Method 1
Incorporating a surfactant, specifically D-α-Tocopheryl polyethylene glycol 1000 succinate (TPGS), an ester of tocopherol, polyethylene glycol, and a dicarboxylic acid, into a solid pharmaceutical composition enhances the bioavailability of the compound.
Data Source
AI summary
A pharmaceutical composition of pyrazole compound and a surfactant and a method of using the same to treat atopic dermatitis.